Stem definition | Drug id | CAS RN |
---|---|---|
644 | 73963-72-1 |
Dose | Unit | Route |
---|---|---|
0.20 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 7.73 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 15, 1999 | FDA | OTSUKA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cerebral infarction | 94.31 | 15.39 | 49 | 5537 | 23317 | 46657159 |
Ventricular fibrillation | 40.40 | 15.39 | 22 | 5564 | 11474 | 46669002 |
Cardiac failure | 35.93 | 15.39 | 46 | 5540 | 79902 | 46600574 |
Acinetobacter test positive | 32.09 | 15.39 | 6 | 5580 | 82 | 46680394 |
Nikolsky's sign | 30.48 | 15.39 | 6 | 5580 | 109 | 46680367 |
Cerebral haemorrhage | 28.35 | 15.39 | 25 | 5561 | 28346 | 46652130 |
Anaemia | 26.73 | 15.39 | 79 | 5507 | 255700 | 46424776 |
Urticaria vesiculosa | 26.58 | 15.39 | 4 | 5582 | 12 | 46680464 |
Aortic dissection | 25.90 | 15.39 | 9 | 5577 | 1583 | 46678893 |
Pyogenic granuloma | 24.71 | 15.39 | 6 | 5580 | 296 | 46680180 |
Drug ineffective | 24.67 | 15.39 | 27 | 5559 | 677811 | 46002665 |
Cardiac failure congestive | 24.08 | 15.39 | 41 | 5545 | 91709 | 46588767 |
Beta-N-acetyl-D-glucosaminidase increased | 22.73 | 15.39 | 4 | 5582 | 38 | 46680438 |
Interstitial lung disease | 22.60 | 15.39 | 30 | 5556 | 53919 | 46626557 |
Ventricular tachycardia | 21.18 | 15.39 | 17 | 5569 | 16950 | 46663526 |
Hepatic function abnormal | 20.71 | 15.39 | 23 | 5563 | 34398 | 46646078 |
Haemorrhage subcutaneous | 20.64 | 15.39 | 9 | 5577 | 2897 | 46677579 |
Gastrointestinal haemorrhage | 19.54 | 15.39 | 34 | 5552 | 77339 | 46603137 |
Torsade de pointes | 19.17 | 15.39 | 14 | 5572 | 12140 | 46668336 |
Parotid gland enlargement | 18.97 | 15.39 | 6 | 5580 | 788 | 46679688 |
Blood urea increased | 18.92 | 15.39 | 19 | 5567 | 25333 | 46655143 |
Subarachnoid haemorrhage | 17.94 | 15.39 | 13 | 5573 | 11140 | 46669336 |
Blood pressure decreased | 16.95 | 15.39 | 27 | 5559 | 57132 | 46623344 |
Acute leukaemia | 16.85 | 15.39 | 6 | 5580 | 1132 | 46679344 |
Kounis syndrome | 16.53 | 15.39 | 6 | 5580 | 1196 | 46679280 |
Liver disorder | 16.03 | 15.39 | 21 | 5565 | 37225 | 46643251 |
Melaena | 15.75 | 15.39 | 18 | 5568 | 27754 | 46652722 |
Enterobacter test positive | 15.71 | 15.39 | 4 | 5582 | 240 | 46680236 |
Shock | 15.62 | 15.39 | 16 | 5570 | 21829 | 46658647 |
Peripheral arterial occlusive disease | 15.50 | 15.39 | 8 | 5578 | 3744 | 46676732 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cerebral infarction | 125.65 | 14.14 | 86 | 9108 | 26287 | 29916997 |
Hepatic function abnormal | 68.49 | 14.14 | 74 | 9120 | 41871 | 29901413 |
Interstitial lung disease | 60.39 | 14.14 | 83 | 9111 | 60114 | 29883170 |
Peripheral arterial occlusive disease | 59.82 | 14.14 | 30 | 9164 | 5138 | 29938146 |
Haemorrhage subcutaneous | 35.08 | 14.14 | 16 | 9178 | 2221 | 29941063 |
Altered state of consciousness | 33.99 | 14.14 | 36 | 9158 | 19883 | 29923401 |
Sprue-like enteropathy | 31.04 | 14.14 | 9 | 9185 | 338 | 29942946 |
Toxicity to various agents | 29.31 | 14.14 | 9 | 9185 | 177174 | 29766110 |
Intermittent claudication | 28.92 | 14.14 | 14 | 9180 | 2220 | 29941064 |
Thrombosis in device | 25.53 | 14.14 | 15 | 9179 | 3511 | 29939773 |
Hemiplegia | 25.42 | 14.14 | 19 | 9175 | 6642 | 29936642 |
Cerebral haemorrhage | 25.22 | 14.14 | 40 | 9154 | 32847 | 29910437 |
Decreased appetite | 24.58 | 14.14 | 101 | 9093 | 149809 | 29793475 |
Gastric ulcer haemorrhage | 24.49 | 14.14 | 17 | 9177 | 5297 | 29937987 |
Lacunar infarction | 24.37 | 14.14 | 14 | 9180 | 3141 | 29940143 |
Renal impairment | 23.73 | 14.14 | 68 | 9126 | 84116 | 29859168 |
Haematochezia | 22.71 | 14.14 | 39 | 9155 | 34183 | 29909101 |
Drug ineffective | 22.63 | 14.14 | 44 | 9150 | 340343 | 29602941 |
Gastrointestinal haemorrhage | 22.17 | 14.14 | 66 | 9128 | 83380 | 29859904 |
Cardiac failure | 21.24 | 14.14 | 65 | 9129 | 83353 | 29859931 |
Cerebral hyperperfusion syndrome | 21.13 | 14.14 | 5 | 9189 | 83 | 29943201 |
Pneumonia aspiration | 19.94 | 14.14 | 39 | 9155 | 37741 | 29905543 |
Carotid artery stenosis | 19.39 | 14.14 | 14 | 9180 | 4640 | 29938644 |
Thrombotic cerebral infarction | 19.06 | 14.14 | 6 | 9188 | 299 | 29942985 |
Contrast encephalopathy | 18.87 | 14.14 | 4 | 9190 | 39 | 29943245 |
Thalamus haemorrhage | 18.73 | 14.14 | 8 | 9186 | 950 | 29942334 |
Gastric cancer | 18.62 | 14.14 | 14 | 9180 | 4936 | 29938348 |
Peripheral artery occlusion | 18.53 | 14.14 | 9 | 9185 | 1437 | 29941847 |
Depressed level of consciousness | 18.43 | 14.14 | 38 | 9156 | 38184 | 29905100 |
Basal ganglia haematoma | 17.41 | 14.14 | 4 | 9190 | 58 | 29943226 |
Acute myocardial infarction | 17.13 | 14.14 | 45 | 9149 | 52894 | 29890390 |
Disseminated intravascular coagulation | 17.04 | 14.14 | 27 | 9167 | 22144 | 29921140 |
Peripheral artery restenosis | 16.87 | 14.14 | 3 | 9191 | 10 | 29943274 |
Fat embolism | 16.71 | 14.14 | 5 | 9189 | 210 | 29943074 |
Arterial restenosis | 16.16 | 14.14 | 4 | 9190 | 81 | 29943203 |
Peripheral vascular disorder | 15.83 | 14.14 | 13 | 9181 | 5206 | 29938078 |
Drug eruption | 15.81 | 14.14 | 23 | 9171 | 17503 | 29925781 |
Shock haemorrhagic | 15.37 | 14.14 | 17 | 9177 | 9848 | 29933436 |
Hypoglycaemia | 15.15 | 14.14 | 42 | 9152 | 50939 | 29892345 |
Chronic pigmented purpura | 15.13 | 14.14 | 4 | 9190 | 106 | 29943178 |
Haemobilia | 15.12 | 14.14 | 5 | 9189 | 292 | 29942992 |
Angioplasty | 14.98 | 14.14 | 7 | 9187 | 1027 | 29942257 |
Liver disorder | 14.86 | 14.14 | 30 | 9164 | 29692 | 29913592 |
Tachycardia | 14.78 | 14.14 | 53 | 9141 | 73686 | 29869598 |
Transient ischaemic attack | 14.51 | 14.14 | 27 | 9167 | 25173 | 29918111 |
Ventricular tachycardia | 14.28 | 14.14 | 26 | 9168 | 23836 | 29919448 |
Blood pressure decreased | 14.21 | 14.14 | 39 | 9155 | 47036 | 29896248 |
Venous haemorrhage | 14.18 | 14.14 | 3 | 9191 | 29 | 29943255 |
Source | Code | Description |
---|---|---|
ATC | B01AC23 | BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin |
FDA MoA | N0000175086 | Phosphodiesterase 3 Inhibitors |
FDA EPC | N0000175598 | Phosphodiesterase 3 Inhibitor |
MeSH PA | D018927 | Anti-Asthmatic Agents |
MeSH PA | D001993 | Bronchodilator Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D005343 | Fibrinolytic Agents |
MeSH PA | D006401 | Hematologic Agents |
MeSH PA | D018696 | Neuroprotective Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D058987 | Phosphodiesterase 3 Inhibitors |
MeSH PA | D010726 | Phosphodiesterase Inhibitors |
MeSH PA | D010975 | Platelet Aggregation Inhibitors |
MeSH PA | D020011 | Protective Agents |
MeSH PA | D019141 | Respiratory System Agents |
MeSH PA | D014665 | Vasodilator Agents |
CHEBI has role | CHEBI:35523 | bronchodilator agents |
CHEBI has role | CHEBI:35620 | vasodilator |
CHEBI has role | CHEBI:48676 | fibrin modulating agents |
CHEBI has role | CHEBI:50249 | anticoagulante |
CHEBI has role | CHEBI:50427 | platelet aggregation inhibitors |
CHEBI has role | CHEBI:50568 | cyclic nucleotide phosphodiesterase inhibitor |
CHEBI has role | CHEBI:63726 | neuroprotective agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Intermittent claudication | indication | 63491006 | DOID:3669 |
Chronic heart failure | contraindication | 48447003 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Disease of liver | contraindication | 235856003 | DOID:409 |
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Enzyme | INHIBITOR | IC50 | 6.70 | IUPHAR | CHEMBL | |||
Cytochrome P450 2C9 | Enzyme | IC50 | 5 | DRUG MATRIX | |||||
cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Enzyme | INHIBITOR | IC50 | 6.42 | IUPHAR |
ID | Source |
---|---|
4021153 | VUID |
N0000148605 | NUI |
D01896 | KEGG_DRUG |
4021153 | VANDF |
C0055729 | UMLSCUI |
CHEBI:31401 | CHEBI |
CHEMBL799 | ChEMBL_ID |
DB01166 | DRUGBANK_ID |
D000077407 | MESH_DESCRIPTOR_UI |
2754 | PUBCHEM_CID |
7148 | IUPHAR_LIGAND_ID |
5680 | INN_ID |
N7Z035406B | UNII |
21107 | RXNORM |
14036 | MMSL |
60734 | MMSL |
7889 | MMSL |
d04382 | MMSL |
007339 | NDDF |
116087001 | SNOMEDCT_US |
395239000 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0028 | TABLET | 50 mg | ORAL | ANDA | 27 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-0044 | TABLET | 100 mg | ORAL | ANDA | 27 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2064 | TABLET | 100 mg | ORAL | ANDA | 28 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-2065 | TABLET | 50 mg | ORAL | ANDA | 28 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0123 | TABLET | 50 mg | ORAL | ANDA | 29 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0223 | TABLET | 100 mg | ORAL | ANDA | 29 sections |
CILOSTAZOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-285 | TABLET | 100 mg | ORAL | ANDA | 22 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-5329 | TABLET | 50 mg | ORAL | ANDA | 28 sections |
cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-176 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-177 | TABLET | 100 mg | ORAL | ANDA | 20 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5411 | TABLET | 100 mg | ORAL | ANDA | 16 sections |
cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-2521 | TABLET | 50 mg | ORAL | ANDA | 20 sections |
cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-2522 | TABLET | 100 mg | ORAL | ANDA | 20 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-3844 | TABLET | 50 mg | ORAL | ANDA | 26 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-4123 | TABLET | 100 mg | ORAL | ANDA | 26 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-050 | TABLET | 50 mg | ORAL | ANDA | 29 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-051 | TABLET | 100 mg | ORAL | ANDA | 29 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-156 | TABLET | 50 mg | ORAL | ANDA | 28 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-157 | TABLET | 100 mg | ORAL | ANDA | 28 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-2200 | TABLET | 100 mg | ORAL | ANDA | 28 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-2208 | TABLET | 50 mg | ORAL | ANDA | 28 sections |
cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-2714 | TABLET | 100 mg | ORAL | ANDA | 20 sections |
Cilostazol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71610-037 | TABLET | 100 mg | ORAL | ANDA | 29 sections |
CILOSTAZOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72189-116 | TABLET | 50 mg | ORAL | ANDA | 16 sections |